Chorioretinopathy: Causes, Symptoms, and Treatment

Central serous chorioretinopathy (CSC) is the most common vision-threatening condition in a family of diseases that affect the choroid and retina at the back of the eye. It develops when fluid leaks under the retina and pools beneath the macula, the area responsible for sharp central vision. CSC tends to strike working-age adults, with men affected far more often than women, and its triggers range from corticosteroid medications to psychological stress. While most acute episodes resolve on their own within a few months, chronic or recurring cases can cause lasting visual damage and a measurable drop in quality of life.

What Happens Inside the Eye

The choroid is a layer of blood vessels sandwiched between the retina and the tough outer wall of the eye. In CSC, these choroidal vessels become abnormally thickened and leaky. Fluid seeps upward through the retinal pigment epithelium (RPE), a single-cell layer that normally acts as a barrier and pump, keeping the space beneath the retina dry. When the choroid pushes too much fluid through and the RPE cannot pump it away fast enough, a blister of fluid forms under the macula. Research on episode duration has shown that the degree of choroidal thickening and the height of RPE disruption at the leak site predict how long an episode will last and how likely it is to become chronic.¹

CSC sits within a broader group of conditions now called the pachychoroid disease spectrum, all of which share the hallmark of an abnormally thick choroid. Among these related disorders, CSC is the most frequent cause of vision loss, specifically because of the subretinal fluid that accumulates in the macula.² A newer imaging-based classification system sorts CSC into simple, complex, atypical, and “no CSC” categories. Eyes classified as complex are more likely to develop abnormal new blood vessel growth beneath the retina, and that complication tends to show up in older patients.³

Corticosteroids Are the Best-Documented Trigger

If there is one risk factor that stands above the rest, it is exposure to corticosteroids. These drugs are widely prescribed for conditions like asthma, allergies, autoimmune diseases, and joint pain, and they come in many forms: pills, injections, nasal sprays, inhalers, and skin creams. A meta-analysis pooling data from over 2,600 people found that those who had used corticosteroids carried roughly four times the odds of developing CSC compared with non-users. The risk held for oral, injected, and nasal spray routes, though inhaled steroids did not reach a statistically significant association.⁴

A large population-based study in South Korea put the increased risk in more concrete terms: people who had ever used corticosteroids had roughly 1.8 times the hazard of developing CSC compared with those who never had, and the risk climbed with longer or more recent use.⁵ Even forms of steroid exposure that patients might not think of as risky, such as joint injections or nasal sprays, have been linked to the condition. In one case-control study, more than half of CSC patients had a history of exogenous steroid use, compared with fewer than one in five matched controls, and two additional patients had Cushing’s syndrome, which raises the body’s own cortisol production.⁶

Because of this well-established connection, stopping all corticosteroid use is the first management step when CSC is diagnosed. Case reports have documented improvement within a week of tapering off oral prednisolone.⁷ Guidelines now recommend discontinuing every form of steroid when possible, along with lifestyle modifications for stress and treatment for sleep apnea where relevant.⁸

Stress, Personality, and the Cortisol Connection

The link between psychological stress and CSC has been discussed since the 1980s. The leading theory is that chronically stressed individuals produce higher levels of circulating catecholamines and cortisol, which essentially mimic the effect of exogenous steroids on the choroid. The construct of the “type-A personality,” characterized by competitiveness, urgency, and a tendency toward hostility, has become a familiar part of the CSC literature, dating back to work by researcher Lawrence Yannuzzi.⁹

More recent work has drilled into specific personality traits rather than relying on the broad type-A label. One study found that patients with acute CSC scored slightly higher on traits like warmth and perfectionism compared with controls.¹⁰ The evidence here is suggestive rather than definitive. Personality research in CSC tends to involve small samples, and separating cause from effect is tricky: the visual disturbance itself could heighten anxiety scores. Still, stress management is now widely recommended alongside medical treatment, and clinicians routinely ask about life stressors when they see a new CSC case.

Other Risk Factors

Beyond steroids and stress, a few other factors appear in the research. Obstructive sleep apnea (OSA) was initially reported as strongly linked to CSC, but at least one well-controlled study found no significant difference when researchers carefully matched patients by body mass index, suggesting the earlier associations may have been driven by shared obesity rather than by OSA itself.¹¹ That does not mean sleep apnea is irrelevant; it may still contribute through blood-pressure swings and hypoxia during sleep. But the connection is muddier than the steroid link.

Genetics also play a role. A genome-wide association study identified a region on chromosome 1, in the complement factor H (CFH) gene, that reached strong significance for chronic CSC. The risk variant accounted for more than a third of the population-attributable risk in one analysis.¹² Larger follow-up work confirmed the same variant and implicated the complement cascade, part of the immune system involved in inflammation and tissue defense.¹³ This is noteworthy because the same CFH gene region is also a major risk locus for age-related macular degeneration, a very different disease of the macula. The overlap suggests shared choroidal vulnerability even when the clinical picture looks nothing alike.

What CSC Feels Like

The hallmark symptom is a blurry or dim spot in the center of your vision, typically in just one eye. Patients often describe objects looking slightly smaller than they should (micropsia) or warped and distorted (metamorphopsia). Colors may appear washed out, and some people report that straight lines seem bent. In a study of 33 patients, nearly half had measurable metamorphopsia on testing charts.¹⁴ These symptoms are captured more broadly in clinical reviews as a dark spot in the center of vision accompanied by micropsia and metamorphopsia, usually affecting one eye.¹⁵

Because the fluid blister distorts the retina’s geometry, vision can fluctuate day to day. Some people notice their vision is worse in bright light, while others find it harder to see in low light. The condition can also cause a mild shift in color perception in the affected eye. These symptoms are usually subtle enough that someone might initially blame fatigue or a need for new glasses, which can delay the trip to an eye doctor.

How Doctors Confirm the Diagnosis

A retina specialist can often spot CSC during a dilated eye exam, but confirming it and ruling out other conditions requires imaging. Optical coherence tomography (OCT) is the workhorse tool: it produces cross-sectional images of the retina and shows the pocket of subretinal fluid clearly. Newer swept-source OCT also reveals choroidal thickening, which supports the diagnosis. Fluorescein angiography, where a fluorescent dye is injected into a vein and photographed as it circulates through the retinal blood vessels, can pinpoint the leak site. And for mapping the full extent of choroidal involvement, indocyanine green angiography (ICGA) is particularly useful. In one study of chronic CSC, every single eye examined showed areas of choroidal vessel leakiness on ICGA that peaked in the middle phase of imaging.¹⁶ The evolution of these imaging techniques has fundamentally reshaped how clinicians understand and manage the disease.¹⁷

Acute Versus Chronic CSC and the Risk of Recurrence

Most first episodes of CSC resolve spontaneously within one to four months, and many patients recover their full visual acuity. In a long-term follow-up study, about two-thirds of eyes maintained stable or improved vision over the observation period. But the recurrence rate is substantial: roughly 30% of eyes had a recurrence within ten years. A small but meaningful fraction of acute cases (around 8% in that cohort) progressed to chronic CSC, defined by persistent or recurrent fluid lasting beyond several months.¹⁸

Chronic CSC is the more worrisome scenario. Prolonged fluid under the retina gradually damages the photoreceptors and RPE, leading to permanent visual changes. About one in four eyes in the same study experienced significant vision loss over the follow-up period. On top of that, nearly a quarter of eyes developed new abnormal blood vessels (choroidal neovascularization) by the end of follow-up, with a cumulative ten-year rate of about 17%. Older age and a higher number of recurrences were the main predictors of this complication.¹⁸ Other estimates of neovascularization rates in CSC broadly range from about 2% to 9% of cases.¹⁹

Treatment Options

For a first, uncomplicated episode, many retina specialists recommend watchful waiting for two to three months, since spontaneous resolution is common. During this window, the focus is on removing triggers: stopping any corticosteroids, reducing stress, and treating sleep-disordered breathing if present.⁸ When the fluid persists or recurs, several active treatments come into play.

Photodynamic Therapy

Half-dose verteporfin photodynamic therapy (PDT) is widely considered the strongest intervention for chronic CSC. A light-sensitive drug is infused intravenously, and a non-thermal laser activates it in the choroid, sealing leaky vessels without burning the retina. In a head-to-head trial against micropulse laser for chronic CSC, half-dose PDT achieved complete fluid resolution in about two-thirds of patients at the final visit, compared with roughly 29% in the micropulse laser group. Visual acuity gains and retinal sensitivity improvements were also significantly greater with PDT.²⁰

Subthreshold Micropulse Laser

Micropulse laser delivers energy in rapid on-off bursts, heating the RPE just enough to stimulate a healing response without leaving a visible scar. For acute CSC, it performs comparably to half-dose PDT: one trial found fluid resorption rates and retinal sensitivity were statistically similar between the two approaches over twelve months.²¹ Another study of chronic CSC patients actually found a higher treatment response rate with micropulse laser (79%) than with PDT (59%) and a greater reduction in central retinal thickness.²² The discrepancy between these studies reflects differences in patient selection, laser protocols, and outcome definitions, and it is one reason the field has not settled on a single standard approach. Many clinicians use micropulse laser as a first-line option because of its favorable safety profile, reserving PDT for cases that do not respond.

Oral Medications

Mineralocorticoid receptor antagonists, specifically spironolactone and eplerenone, have generated cautious excitement. These drugs block a hormone pathway thought to contribute to choroidal vessel leakiness. A randomized crossover trial found that spironolactone significantly reduced subretinal fluid and choroidal thickness compared with placebo, though visual acuity did not improve significantly within the short study period.²³ Eplerenone, a newer drug in the same class with fewer hormonal side effects, has shown improvements in both fluid and visual acuity across several smaller studies. However, most evidence comes from retrospective data, and patients with advanced RPE changes are less likely to benefit, suggesting that earlier treatment works better.²⁴

Anti-VEGF Injections for Neovascular Complications

When CSC is complicated by abnormal blood vessel growth beneath the retina, anti-VEGF injections become relevant. These drugs, injected directly into the eye, block the growth signal driving new vessels. A multicenter study confirmed that anti-VEGF monotherapy is safe and effective for this complication.²⁵ That said, fluid resorption is often incomplete. In one cohort, about 45% of eyes still had residual fluid one month after an average of nearly three injections, meaning many patients need ongoing treatment or a switch to PDT.²⁶ Anti-VEGF injections are not used for routine CSC without neovascularization; their role is specifically in managing this secondary complication.

How CSC Affects Daily Life

The visual distortions of CSC go beyond what an eye chart captures. Patients with chronic CSC score significantly worse than healthy people on nearly every category of a standardized vision-related quality-of-life questionnaire, including near activities, distance activities, social functioning, mental health, and driving.²⁷ Even when measured visual acuity is only mildly reduced, the metamorphopsia and contrast-sensitivity loss make tasks like reading, working at a computer, and driving at night harder than the numbers suggest.

Psychological distress is also common. Patients with CSC report significantly higher levels of distress across multiple psychological domains compared with matched controls, and lower overall quality of life in all areas except bodily pain.²⁸ The longer the disease lasts, the worse peripheral-vision-related quality of life becomes, and patients with chronic CSC report lower social functioning than those with resolved acute episodes.²⁹ This creates something of a vicious cycle: stress can trigger or worsen CSC, and living with impaired vision generates more stress.

Birdshot and Other Chorioretinopathies

CSC is by far the most frequently discussed chorioretinopathy, but the broader category includes several other conditions with different causes and outlooks. Birdshot chorioretinopathy is one of the rarer forms, an autoimmune disease in which the body’s immune system attacks the choroid and retina, producing scattered cream-colored lesions that resemble birdshot pellet marks. It is strongly associated with a specific genetic marker, HLA-A29, and typically causes floaters, hazy vision, and gradual visual-field loss in both eyes.³⁰ Unlike CSC, which is driven by choroidal vascular dysfunction and fluid leakage, birdshot is an inflammatory disease that requires immunosuppressive treatment. The two conditions can occasionally be confused on initial examination because both affect the choroid, but their imaging patterns, lab findings, and management are fundamentally different.

Other conditions in this family include multifocal choroiditis, punctate inner choroidopathy, and serpiginous choroidopathy, each with its own pattern of inflammation and retinal damage. What they share with CSC is involvement of the choroid, but their underlying mechanisms and the populations they affect differ substantially. A retina specialist uses the combination of imaging, lab tests, and clinical history to sort these out, and getting the diagnosis right matters because the treatments point in opposite directions: immunosuppression for the inflammatory types, steroid avoidance for CSC.